Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
2 September 2020Portfolio NewsClarify Medical Now Approved as a MultiPlan Participating Provider
1 September 2020Portfolio NewsBicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
19 August 2020Portfolio NewsCentauri Health Solutions Announces Acquisition of HCFS- 12 August 2020Portfolio NewsCentauri Health Solutions Ranks No. 448 on the 2020 Inc. 5000 List of America’s Fastest-Growing Private Companies
- 11 August 2020Portfolio NewsBicycle Therapeutics Appoints Dr. Dominic Smethurst as Chief Medical Officer
- 10 August 2020SV NewsSV Health Investors discuss the firm’s new $90M early-stage Medtech Convergence Fund
4 August 2020Portfolio NewsRibometrix Further Expands Leadership with Appointment of Barclay "Buck" Phillips as Chief Operating Officer and Chief Financial Officer- 4 August 2020Portfolio NewsCentauri Health Solutions Adds New Analytics Capabilities with Acquisition of AppRev
- 4 August 2020Portfolio NewsCatabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
23 July 2020Portfolio NewsXilio Therapeutics Appoints Paul J. Clancy to its Board of Directors
22 July 2020Portfolio NewsExcellent news today from our portfolio company @Cerevance on the expansion of its Series B financing round, adding a further $20 million to the $45 million announced in April.
21 July 2020Portfolio NewsHealthify Partners with Ride Health to Provide Non-Medical Transportation Services to People in Need
